Telehealth buprenorphine care for people with opioid use disorder in vulnerable settings
Official title: Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Run by Boulder Care · NCT07169409 · Data updated 2026-11-12
This project will see if Boulder Care's telehealth platform can deliver buprenorphine treatment effectively to people with opioid use disorder in vulnerable communities.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Boulder Care Industry-sponsored |
| Locations | 1 site (Portland, Oregon) |
| Status | Recruiting |
| Started | June 10, 2025 |
| Main results expected | August 2027 |
| Study ends | September 15, 2027 |
| Registry record updated | September 11, 2025 |
| Trial ID | NCT07169409 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking adults with opioid use disorder who are starting or restarted buprenorphine within the past 45 days and can receive care through Boulder Care in Portland.
✕Probably not a fit
People allergic to buprenorphine, those planning to move out of a Boulder Care-affiliated state within a year, or those with untreated medical or mental conditions preventing participation are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1 interventional study tests a telemedicine-delivered buprenorphine program offered by Boulder Care in partnership with NIDA, focusing on vulnerable and culturally specific populations. Participants are English-speaking adults with a history of opioid use disorder who are starting buprenorphine or are within 45 days of starting or restarting it. The protocol delivers medication and care through Boulder Care's telehealth platform at a Portland, Oregon site and monitors feasibility, reach, equity, and early clinical outcomes. Key exclusions include buprenorphine allergy, plans to leave a Boulder Care-affiliated state within 12 months, and untreated health conditions that would preclude participation.
Why it matters
Potential benefit: If successful, it could expand convenient, culturally sensitive access to buprenorphine care for underserved people with opioid use disorder and improve treatment retention.
How similar studies have gone: Previous studies have shown telehealth-delivered buprenorphine can improve access and retention, but this platform- and equity-focused implementation approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of Opioid Use Disorder (OUD) * Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication * Speak and understand English Exclusion Criteria: * History of allergic reaction to buprenorphine * Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care) * Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation
Where it's running
-
Boulder Care
Portland, Oregon, United States Recruiting
Study contacts
- Study coordinator: Andrea Baron, MPH
- Email: andrea.baron@boulder.care
- Phone: 408-483-2766
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand
This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.
-
STORC: Training a support person plus patient navigation after birth
We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.
-
Personalized Addiction Treatment Enhancement for Opioid Use Disorder
A digital platform run by peer recovery supporters will be tested to help adults with opioid use disorder who are on buprenorphine or methadone stay in treatment and improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.